Trump Adds Nine Drugmakers to Pharma Pricing Deal, Easing Overhang for Bitcoin (BTC)

President Donald Trump announced the addition of nine pharmaceutical manufacturers to his drug-pricing framework, expanding the program to 26 companies representing roughly 90% of the U.S. pharmaceutical market. The newly added companies, which include Teva Pharmaceuticals, Alcon, and Astellas Pharma, collectively committed $19.6 billion toward domestic manufacturing and agreed to offer discounted prices to state Medicaid programs. The administration estimates that total savings from agreements over the past year exceed $600 billion. Financial analysts view the development favorably for broader markets, noting that the drug pricing framework removes a key regulatory overhang that previously clouded healthcare equities. UBS highlighted that clinical successes and easing policy uncertainty have supported strong sector gains, with biotech equities outperforming many standard benchmarks over the past year. The reduction in regulatory uncertainty offers positive macro read-throughs for risk assets, including cryptocurrencies and high-beta technology equities. Bitcoin (BTC) held steady around $78,362 while Ethereum traded near $2,461, demonstrating market resilience as broader macro clarity supports risk-on investor sentiment.